Financial Health Assessment: VIRAMAL LIMITED

1. Financial Health Score: D+

Rationale: This is a pre-revenue biotechnology company with significant accumulated losses, negative working capital, and an explicit going concern uncertainty disclosed in its accounts. While the company has successfully raised external funding historically and shows a positive net asset position on paper, the underlying operational cash dynamics present material financial risk. The score reflects the precarious position common to development-stage life sciences companies, but one that requires urgent attention to funding pipelines.

2. Key Vital Signs

Liquidity Pulse — Critical

Reading the pulse: A current ratio of 0.20:1 is the financial equivalent of severe hypotension — the company's short-term obligations outstrip its liquid resources by a factor of nearly five. This means for every £1 of short-term debt, the company has only 20p to pay it. This is a dangerously thin liquidity position.

Cash Blood Pressure — Weak and Declining

Reading the pulse: Cash has recovered slightly from the 2024 trough, but remains a fraction of the 2022 peak. The modest uptick to £85,044 likely reflects the equity raise evidenced by the increase in share premium, but the absolute level remains concerning for a company with 11 employees and ongoing R&D expenditure.

Capital Health — Superficially Stable, Structurally Fragile

Reading the pulse: The share premium account increased by approximately £398,000, indicating fresh equity investment during the period — a positive sign that investors remain willing to fund the business. However, the P&L reserve has deteriorated significantly from (£338,936) to (£721,611), representing accumulated losses that have more than doubled in a single period.

Asset Composition — Concentration Risk

Reading the pulse: Nearly 80% of the company's assets are tied up in subsidiary investments — illiquid and difficult to realize quickly. The tangible assets are fully depreciated (net book value of zero), and the company has minimal liquid assets relative to its obligations.

3. Diagnosis

Primary Condition: Pre-Revenue Cash Burn Syndrome

The financial data reveals a company in the classic "valley of death" phase of biotech development. The directors' own going concern disclosure confirms this diagnosis:

"The company carries out research and development and, to date, has not generated any revenue from its primary activities. As a consequence, it is reliant on raising external funding to continue its activities."

This is the financial equivalent of a patient on life support — survival depends entirely on the continued supply of external resources (funding).

Symptom Analysis:

🔴 Accumulated Losses accelerating — The P&L reserve has worsened from (£338,936) to (£721,611), a deterioration of £382,675. This represents the annual loss and confirms the company is burning through cash rapidly.

🔴 Negative working capital — Net current liabilities of £596,993 mean the company cannot meet its short-term obligations from current assets. This creates a structural dependency on either continued creditor forbearance or fresh funding rounds.

🟡 Investment-heavy balance sheet — The £1.703M investment in subsidiaries (likely the Swedish operations referenced on the website) provides a theoretical asset backing, but these are illiquid and carried at cost less impairment. The £159,712 impairment provision suggests some deterioration has already been recognized.

🟡 Equity raises providing oxygen — The increase in share premium from £270,685 to £668,932 indicates approximately £398,000 of new equity was raised, which has kept the company afloat and slightly improved net assets.

🟢 Filing compliance — Accounts are filed on time and the company maintains Active status. The reduction in headcount from 13 to 11 employees suggests some cost discipline.

🟢 Intangible assets (IP) retaining value — Intellectual property with a net book value of £276,830 continues to be carried, suggesting the company believes its patents remain viable commercial assets.

Secondary Condition: Structural Dependency

The company is a holding/parent entity that appears to operate through subsidiaries. This creates a dual dependency: 1. On external funders for capital 2. On subsidiaries for eventual commercial returns

Neither dependency has yet produced revenue, making the company structurally vulnerable to any disruption in funding availability.

4. Prognosis

Short-term (6-12 months): Guarded

The company has sufficient net assets on paper (£1.36M) and recently raised equity, but the cash position (£85,044) and negative working capital create immediate vulnerability. If the next funding round is delayed or fails, the company would face a severe liquidity crisis within months.

Medium-term (1-3 years): Uncertain

The biotech sector is inherently high-risk, and the company's focus on women's health biological products represents a potentially attractive niche. However, the path from R&D to commercial revenue is long and expensive. The company will likely require multiple further funding rounds.

Key Risk Factors:

• Funding risk — Explicitly acknowledged in the going concern note
• Cash burn rate — Estimated annual loss of approximately £380,000+
• No revenue visibility — No indication of imminent product commercialization
• Illiquid asset base — 80% of assets are in subsidiary investments

Positive Indicators:

• Successful history of raising equity funding
• Specialized niche (women's health biotech) with market potential
• Continued investor confidence evidenced by recent share premium increase
• Active development of IP portfolio

5. Recommendations

Immediate Actions (Critical)

1. Cash Flow Stabilization — Implement rigorous 13-week cash flow forecasting. With only £85,044 in cash and significant current liabilities, the company must manage its cash runway with precision.

2. Working Capital Management — Negotiate extended payment terms with creditors where possible. The £750,745 in current liabilities needs careful management to avoid creditor pressure.

3. Funding Pipeline — Begin conversations for the next funding round immediately. Given the cash burn rate, the company should target raising 18-24 months of operating capital.

Medium-term Actions (Important)

4. Revenue Pathway Definition — Articulate a clear timeline to first revenue. Even early-stage licensing deals or milestone payments would improve the financial profile.

5. Cost Optimization — The headcount reduction from 13 to 11 is a start, but further review of non-core expenditure is warranted given the pre-revenue status.

6. Subsidiary Value Monitoring — Regular impairment reviews of the £1.703M subsidiary investment are essential. Any further impairment would erode the net asset position significantly.

7. Stakeholder Communication — Maintain transparent communication with investors about funding needs, timelines, and milestones. The going concern disclosure, while honest, may concern some stakeholders if not accompanied by a clear funding strategy.